AgingResearch.NewsJoin free

Aspen Neuroscience

CompanyUnited States

Aspen Neuroscience develops one asset, in phase 3 (Sasineprocel in Parkinson's disease). Mostly cell therapy acting on stem cell maintenance; based in the United States.

1
Asset
Furthest stage
Phase 3
Raised
US$586.5m
0
Trials
1
Signal

Pipeline

1

  • Sasineprocel

    Autologous iPSC-derived dopaminergic neuronal precursor cell therapy to replace lost neurons

    Phase 3, Cell therapy, Stem cell maintenance, Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants6
  • Signals3
  • Similar companies6

Intelligence